Infographic | June 14, 2022

Drug Innovators' Outlook On Innovative Treatments

Source: ISR Reports

In Q32021, ISR asked 134 outsourcers of biologic drug substance to provide a little insight into their pipelines and how that might impact their outsourcing practices. Two-thirds (63%) of respondents agree – strongly agree that their company’s focus on new, innovative treatments will impact their outsourcing practices. Roughly one-third of respondents confirmed ADC (37%) and CAR-T (30%) therapies are areas of focus.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Bioprocess Online